<DOC>
	<DOCNO>NCT02704962</DOCNO>
	<brief_summary>The investigator hypothesis antipsychotic drug combination low-dose olanzapine plus low-dose trifluoperazine similar regular-dose olanzapine monotherapy efficacy safety treatment schizophrenia.The goal study compare efficacy safety olanzapine ( 10 mg/d ) olanzapine ( 5 mg/d ) plus trifluoperazine ( 5 mg/d ) treatment acute psychotic exacerbation schizophrenia .</brief_summary>
	<brief_title>Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine</brief_title>
	<detailed_description>Antipsychotic monotherapy recognize treatment choice patient schizophrenia . Surveys show antipsychotic polypharmacy frequently prescribe , yet randomize , double-blind clinical trial examine practice . Olanzapine , atypical antipsychotic agent , low incidence extrapyramidal symptom high cost compare trifluoperazine . It report mean dos typical antipsychotic le 600 mg per day chlorpromazine equivalent high risk extrapyramidal symptom atypical antipsychotic . The objective study compare efficacy safety olanzapine ( 10 mg per day ) olanzapine ( 5 mg per day ) plus trifluoperazine ( 5 mg per day ) treatment acute psychotic exacerbation schizophrenia . In 6-week , double-blind , fixed-dose study , patient schizophrenia randomly assign olanzapine ( 10 mg per day ) ) olanzapine ( 5 mg per day ) plus trifluoperazine ( 5 mg per day ) . The hypothesis two treatment group similar efficacy safety , different cost . The primary efficacy measure change baseline Positive Negative Syndrome Scale ( PANSS ) total score ; secondary outcome include Clinical Global Impression-Severity ( CGI-S ) , Calgary Depression Scale Schizophrenia ( CDSS ) , Global Assessment Functioning Scale ( GAF ) , Short Form-36 ( SF-36 ) , Mini Mental State Examination ( MMSE ) . Safety assessment include change baseline Simpson-Angus Rating Scale ( SAS ) , Abnormal Involuntary Movement Scale ( AIMS ) , Barnes Akathisia Scale ( BAS ) , UKU Side-effects Rating Scale , change baseline prolactin level , body weight , vital sign , blood pressure , Bazett 's correction QT interval ( QTc interval ) , fast glucose level , lipid panel ( cholesterol , high density lipid protein , low density lipid protein , triglyceride ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Trifluoperazine</mesh_term>
	<criteria>physically healthy laboratory parameter within normal limit age 18 55 year satisfy DSMIV criterion schizophrenia baseline Clinical Global ImpressionSeverity Illness ( CGIS ) scale score 4 great DSMIV diagnosis substance abuse dependence ( include alcohol ) receive depot antipsychotic drug precede 3 month give write informed consent participate study full explanation study 's aim procedure . history serious adverse reaction olanzapine trifluoperazine history tardive dyskinesia neuroleptic malignant syndrome female subject pregnant risk pregnancy lactation diagnosis treatmentresistant schizophrenia previously receive clozapine electroconvulsive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>olanzapine</keyword>
	<keyword>trifluoperazine</keyword>
	<keyword>antipsychotic polypharmacy</keyword>
</DOC>